title: Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer.
abstract: The epigenetic regulator BMI1 is upregulated progressively in a wide variety of human tumors including colorectal cancer. In this study, we assessed the requirement for Bmi1 in intestinal tumorigenesis using an autochthonous mouse model in which Apc was conditionally ablated in the intestinal epithelium. Germline mutation of Bmi1 significantly reduced both the number and size of small intestinal adenomas arising in this model, and it acted in a dose-dependent manner. Moreover, in contrast to wild-type controls, Bmi1(-/-) mice showed no increase in median tumor size, and a dramatic decrease in tumor number, between 3 and 4 months of age. Thus, Bmi1 is required for both progression and maintenance of small intestinal adenomas. Importantly, Bmi1 deficiency did not disrupt oncogenic events arising from Apc inactivation. Instead, the Arf tumor suppressor, a known target of Bmi1 epigenetic silencing, was upregulated in Bmi1 mutant tumors. This was accompanied by significant upregulation of p53, which was confirmed by sequencing to be wild-type, and also elevated apoptosis within the smallest Bmi1(-/-) adenomas. By crossing Arf into this cancer model, we showed that Arf is required for the induction of both p53 and apoptosis, and it is a key determinant of the ability of Bmi1 deficiency to suppress intestinal tumorigenesis. Finally, a conditional Bmi1 mutant strain was generated and used to determine the consequences of deleting Bmi1 specifically within the intestinal epithelium. Strikingly, intestinal-specific Bmi1 deletion suppressed small intestinal adenomas in a manner that was indistinguishable from germline Bmi1 deletion. Thus, we conclude that Bmi1 deficiency impairs the progression and maintenance of small intestinal tumors in a cell autonomous and highly Arf-dependent manner.
authors: David H Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA, USA.
authors: M A
authors: MA
authors: Maynard
authors: David H Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA, USA.
authors: R
authors: R
authors: Ferretti
authors: 1] David H Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA, USA [2] Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
authors: K I
authors: KI
authors: Hilgendorf
authors: Institut Cochin-INSERM, Universite Paris V, Paris, France.
authors: C
authors: C
authors: Perret
authors: Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
authors: P
authors: P
authors: Whyte
authors: 1] David H Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA, USA [2] Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
authors: J A
authors: JA
authors: Lees
mesh_terms: D000818:Animals; D017209:Apoptosis; D063646:Carcinogenesis; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D007413:Intestinal Mucosa / Q000378:metabolism; D007414:Intestinal Neoplasms / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D051379:Mice; D063150:Polycomb Repressive Complex 1 / Q000172:deficiency / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000172:deficiency / Q000378:metabolism*
chemical_list: C489421:Bmi1 protein, mouse; C417743:Cdkn2a protein, mouse; D019941:Cyclin-Dependent Kinase Inhibitor p16; D011518:Proto-Oncogene Proteins; D063150:Polycomb Repressive Complex 1
references: Clin Cancer Res. 2006 Dec 1;12(23):6960-6
references: 17145814
references: J Cancer Res Clin Oncol. 2010 Jul;136(7):997-1006
references: 20024662
references: Cell Signal. 2007 Dec;19(12):2428-33
references: 17651940
references: Genes Dev. 1994 Apr 1;8(7):757-69
references: 7926765
references: Genesis. 2000 Feb;26(2):113-5
references: 10686601
references: Nat Genet. 2008 Jul;40(7):915-20
references: 18536716
references: Annu Rev Pathol. 2011;6:479-507
references: 21090969
references: J Biol Chem. 2012 Feb 3;287(6):3760-8
references: 22170051
references: J Neurosci. 2009 Jul 15;29(28):8884-96
references: 19605626
references: Lab Invest. 2004 Dec;84(12):1619-30
references: 15502862
references: Nature. 2011 Sep 18;478(7368):255-9
references: 21927002
references: Cancer Res. 2007 Oct 15;67(20):9721-30
references: 17942902
references: Cell. 2009 Mar 6;136(5):903-12
references: 19269367
references: Cancer Res. 2003 Feb 15;63(4):742-6
references: 12591718
references: Nature. 2009 Jan 29;457(7229):608-11
references: 19092804
references: J Clin Invest. 2005 Jun;115(6):1503-21
references: 15931389
references: Genesis. 2004 Jul;39(3):186-93
references: 15282745
references: Mol Cell Neurosci. 2010 Oct;45(2):151-62
references: 20600931
references: Cold Spring Harb Symp Quant Biol. 2005;70:129-37
references: 16869746
references: Biochem Cell Biol. 2009 Oct;87(5):711-46
references: 19898523
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: Cell Stem Cell. 2007 Jun 7;1(1):87-99
references: 18371338
references: Cell. 1997 Nov 28;91(5):649-59
references: 9393858
references: Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
references: 7568133
references: Nat Genet. 1999 Jan;21(1):70-1
references: 9916792